Update on regulatory review of lecanemab for treatment of early Alzheimer’s disease in the European Union

Posted on by

STOCKHOLM, Jan. 31, 2025 /PRNewswire/ — BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the European Commission has asked the Committee for Medicinal Products for Human Use (CHMP) to consider two additional questions. These questions will now be…